David Westenberg
Stock Analyst at Piper Sandler
(4.09)
# 568
Out of 4,734 analysts
145
Total ratings
52.27%
Success rate
12.37%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKYA Akoya Biosciences | Reiterates: Overweight | $4 → $3 | $2.96 | +1.44% | 7 | Nov 19, 2024 | |
| NTRA Natera | Maintains: Overweight | $150 → $200 | $161.86 | +23.57% | 13 | Nov 18, 2024 | |
| TEM Tempus AI | Reiterates: Neutral | $40 → $70 | $47.54 | +47.24% | 2 | Nov 12, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $2.5 | $1.71 | +46.63% | 6 | Nov 11, 2024 | |
| ILMN Illumina | Maintains: Overweight | $195 → $185 | $141.79 | +30.47% | 14 | Nov 11, 2024 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $26 → $22 | $17.56 | +25.28% | 6 | Nov 11, 2024 | |
| EXAS Exact Sciences | Maintains: Overweight | $85 → $75 | $53.58 | +39.98% | 9 | Nov 11, 2024 | |
| CTKB Cytek Biosciences | Maintains: Overweight | $8 → $8.5 | $5.79 | +46.93% | 8 | Nov 11, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $6 → $7 | $7.27 | -3.71% | 11 | Nov 11, 2024 | |
| IDXX IDEXX Laboratories | Reiterates: Neutral | $520 → $435 | $427.22 | +1.82% | 9 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $165 | $152.28 | +8.35% | 5 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $235 → $240 | $244.06 | -1.66% | 2 | Oct 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $195 → $210 | $167.78 | +25.16% | 11 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $34 | $43.46 | -21.77% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $11.76 | +48.81% | 9 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $12.10 | +32.23% | 8 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $14.26 | +40.25% | 7 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.14 | +40.19% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $16.04 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $43.08 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $47.24 | - | 1 | Nov 21, 2017 |
Akoya Biosciences
Nov 19, 2024
Reiterates: Overweight
Price Target: $4 → $3
Current: $2.96
Upside: +1.44%
Natera
Nov 18, 2024
Maintains: Overweight
Price Target: $150 → $200
Current: $161.86
Upside: +23.57%
Tempus AI
Nov 12, 2024
Reiterates: Neutral
Price Target: $40 → $70
Current: $47.54
Upside: +47.24%
Pacific Biosciences of California
Nov 11, 2024
Maintains: Neutral
Price Target: $2 → $2.5
Current: $1.71
Upside: +46.63%
Illumina
Nov 11, 2024
Maintains: Overweight
Price Target: $195 → $185
Current: $141.79
Upside: +30.47%
Fulgent Genetics
Nov 11, 2024
Maintains: Neutral
Price Target: $26 → $22
Current: $17.56
Upside: +25.28%
Exact Sciences
Nov 11, 2024
Maintains: Overweight
Price Target: $85 → $75
Current: $53.58
Upside: +39.98%
Cytek Biosciences
Nov 11, 2024
Maintains: Overweight
Price Target: $8 → $8.5
Current: $5.79
Upside: +46.93%
Adaptive Biotechnologies
Nov 11, 2024
Maintains: Overweight
Price Target: $6 → $7
Current: $7.27
Upside: -3.71%
IDEXX Laboratories
Nov 4, 2024
Reiterates: Neutral
Price Target: $520 → $435
Current: $427.22
Upside: +1.82%
Oct 28, 2024
Maintains: Neutral
Price Target: $150 → $165
Current: $152.28
Upside: +8.35%
Oct 28, 2024
Maintains: Neutral
Price Target: $235 → $240
Current: $244.06
Upside: -1.66%
Aug 14, 2024
Maintains: Overweight
Price Target: $195 → $210
Current: $167.78
Upside: +25.16%
Aug 13, 2024
Maintains: Overweight
Price Target: $30 → $34
Current: $43.46
Upside: -21.77%
Aug 6, 2024
Maintains: Neutral
Price Target: $17 → $18
Current: $11.76
Upside: +48.81%
Jul 1, 2024
Maintains: Neutral
Price Target: $19 → $16
Current: $12.10
Upside: +32.23%
Feb 26, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $14.26
Upside: +40.25%
Nov 13, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.14
Upside: +40.19%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $16.04
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $43.08
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $47.24
Upside: -